Zeuzem S, et al. - The efficacy and safety of 8-week and 12-week courses of treatment with 300 mg of glecaprevir plus 120 mg of pibrentasvir were evaluated in patients without cirrhosis who had hepatitis C virus (HCV) genotype 1 or 3 infection. High rates of sustained virologic response were achieved by using once-daily treatment with glecaprevir–pibrentasvir for either 8 weeks or 12 weeks among patients with HCV genotype 1 or 3 infection who did not have cirrhosis.